Epigenomics is focused on developing innovative blood screening tests for cancer. Our lead product, Epi proColon, is the only FDA approved colorectal cancer (CRC) screening blood test. Epi proColon is intended for patients who are unable or unwilling to complete a colonoscopy or take-home stool test. These unscreened patients contribute disproportionately to new CRC cases and CRC deaths. Epi proColon has the same detection rate as fecal immunochemical test (FIT) but in the convenience of a blood test. Epi proColon provides a convenient blood based option to address these average-risk, non-adherent patients - the patients you never see.
11055 Flintkote Ave
San Diego, CA 92121